3M and MIT Researchers Developing a Rapid Diagnostic Test for COVID-19 Duplicate 1 - CIMIT MAIN

Responsive Image

We are thrilled to announce that we’ve been selected as one of the first spokes of the ARPA-H Investor Catalyst Hub network!

We are excited to be a part of this nationwide network dedicated to accelerating groundbreaking advances in science and medicine—all in pursuit of better health outcomes for everyone.

Learn more >

Funding Opportunities and Events

News and Annoucements

null 3M and MIT Researchers Developing a Rapid Diagnostic Test for COVID-19 Duplicate 1

3M and MIT Researchers Developing a Rapid Diagnostic Test for COVID-19

The goal is a new, highly accurate, mass-produced low-cost diagnostic device that delivers results in minutes.


ST. PAUL, Minn.--(BUSINESS WIRE)--To help the world respond to COVID-19, 3M and researchers at MIT are testing a new rapid test that detects the virus. Accelerated research is underway to learn if a simple-to-use, diagnostic device can produce highly accurate results within minutes and is feasible to mass manufacture.

The U.S. National Institute of Health selected the rapid COVID-19 test for accelerated development and commercialization support, after rigorous review by an expert panel. The test is in the Rapid Acceleration of Diagnostics Tech (RADx Tech) program, an aggressively-paced COVID-19 diagnostics initiative from the NIH’s National Institute of Biomedical Imaging and Bioengineering.

Read the full release >

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, CIMIT has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.